Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
Rhea-AI Summary
Vaxart (OTCQX: VXRT) will present research on its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 in Atlanta, held October 19–22, 2025.
The presentation, titled “An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Next Generation Oral Bivalent Vaccine Candidate”, is scheduled for Monday, October 20, 2025, 1:45 PM–3:00 PM ET in room B401-B402 and will be delivered by Nicholas J. Bennett, MBBChir, PhD.
Positive
- None.
Negative
- None.
News Market Reaction – VXRT
In the Oct 20 session, VXRT declined 1.39%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research featuring its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 taking place October 19-22, 2025, at the Georgia World Congress Center in Atlanta.
IDWeek Oral Abstract Presentation:
Presentation Title: An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Next Generation Oral Bivalent Vaccine Candidate
Session Title: Late Breaking Trial Results For Viral and Bacterial Infections
Presenter: Nicholas J. Bennett MBBChir, PhD, Vaxart Medical Director
Session Date and Time: Monday, October 20, 2025, 1:45 PM - 3:00 PM ET
Location: B401-B402
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® Verified individual.
